Todd A. Miano, PharmD, PhD

Assistant Professor of Epidemiology in Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania
Department: Biostatistics and Epidemiology
Contact information
University of Pennsylvania
423 Guardian Drive
809 Blockley Hall
Philadelphia, PA 19104
423 Guardian Drive
809 Blockley Hall
Philadelphia, PA 19104
Publications
Education:
PharmD (Pharmacy)
Virginia Commonwealth University, 2006.
MSCE (Master of Science in Clinical Epidemiology)
Perelman School of Medicine at the University of Pennsylvania, 2015.
PhD (Epidemiology)
University of Pennsylvania , 2019.
Permanent linkPharmD (Pharmacy)
Virginia Commonwealth University, 2006.
MSCE (Master of Science in Clinical Epidemiology)
Perelman School of Medicine at the University of Pennsylvania, 2015.
PhD (Epidemiology)
University of Pennsylvania , 2019.
Description of Research Expertise
Dr. Miano is a critical care pharmacist and epidemiologist whose work aims to reduce harm from adverse drug events in acutely ill patients. His research focuses on understanding the determinants and impacts of nephrotoxicity (the syndrome of rapid kidney function loss resulting from drug toxicity), and the health impacts of drug-drug interactions (DDI). Nephrotoxicity is a major, modifiable cause of acute kidney injury (AKI) in hospitalized patients, especially in the setting of polypharmacy, where numerous drug combinations can interact to increase toxicity risk. Nephrotoxic AKI accounts for nearly one third of AKI events in hospitalized patients, and has severe adverse consequences, including increased risk of death and a higher risk of chronic kidney disease onset and progression. To address these public health problems, he leads a translational, acute care pharmacoepidemiology research program that integrates information from observational causal inference studies, prospective molecular epidemiologic studies, and randomized clinical trials to examine the comparative safety of nephrotoxic drugs and to understand underlying molecular mechanisms of toxicity.His work has advanced our understanding of the limitations of current phenotyping methods for nephrotoxic AKI. Serum creatinine, the standard biomarker of nephrotoxicity, is a kidney function biomarker that has poor sensitivity and specificity for kidney parenchymal injury. In a seminal paper, Dr. Miano found that commonly prescribed antibiotics, when used in combination, can lead to false elevations in creatinine, so called pseudo-nephrotoxicity. The study further found that cystatin C, a novel kidney function biomarker, can be used to accurately detect changes in kidney function during antibiotic treatment. This work questions the results of dozens of prior creatinine-based studies and stands to establish a new paradigm for evaluating drug-associated AKI. His lab was also the first to show that kidney disease strongly modifies the severity of drug-drug interactions that are mediated by inhibition of hepatic metabolism, a finding that has mechanistic implications for dozens of drug combinations commonly encountered in clinical practice.
Selected Publications
Miano TA, Hennessy S, Yang W, Dunn TG, Weisman AR, Oniyide O, Agyekum RS, Turner AP, Ittner CAG, Anderson BJ, Wilson FP, Townsend R, Reilly JP, Giannini HM, Cosgriff CV, Jones TK, Meyer NJ, Shashaty MGS: Association of Vancomycin Plus Piperacillin-Tazobactam with Early Changes in Creatinine versus Cystatin C in Critically Ill Adults: A Prospective Cohort Study. Intensive Care Med 48(9): 1144-1155, Jul 2022 Notes: doi: 10.1007/s00134-022-06811-0.Miano TA, Wang L, Leonard CE, Brensinger CM, Acton EK, Dawwas GK, Bilker W, Soprano SE, Pham Nguyen TP, Woody G, Yu E, Neuman M, Li L, Hennessy S: Identifying clinically relevant drug-drug interactions with methadone and buprenorphine: a translational approach to signal detection. Clin Pharmacol Ther 112(5): 1120-1129, July 2022 Notes: doi: 10.1002/cpt.2717.
Miano TA, Yang W, Shashaty MGS, Zuppa A, Brown JR, Hennessy S: The magnitude of the warfarin-amiodarone drug-drug interaction varies with renal function: a propensity-matched cohort study. Clinical Pharmacology and Therapeutics 107: 1446-1456, June 2020.
Miano TA, Shashaty MGS, Yang W, Brown JR, Zuppa A, Hennessy S. : Effect of renin-angiotensin system inhibitors on the comparative nephrotoxicity of NSAIDs and opioids during hospitalization. Kidney360 1(7): 604-613, July 2020.
Vasquez CR, Gupta S, Miano TA, Roche M, Hsu J, Yang W, Holena DN, Reilly JP, Schrauben SJ, Leaf DE, Shashaty MGS; STOP-COVID Investigators.: Identification of distinct clinical subphenotypes in critically ill patients with COVID-19. Chest 160(3): 929-943, Sep 2021.
Miano TA, Flesch JD, Feng R, Forker C, Brown M, Oyster M, Kalman L, Rushefski M, Cantu E, Porteus M, Yang W, Localio AR, Diamond JM, Christie JD, Shashaty MGS. : Early Tacrolimus Concentrations After Lung Transplantation are Predicted by Combined Clinical and Genetic Factors and Associated with Acute Kidney Injury Clinical Pharmacology and Therapeutics 107: 462-470, February 2020.
Roberts RR, Miano TA, Hammond DA, Patel GP, Chen JT, Phillips KM, Lopez N, Kashanl K, Qadir N, Cairns CB, Mathews K, Park P, Khan A, Gilmore JF, Tanner Brown AR, Tsuei B, Handzel M, Chang AL, Duggal A, Lanspa M, Herbert JT, Martinez A, Tonna J, Ammar MA, Nazer LH, Heavner M, Pender E, Chambers L, Kenes MT, Kaufman D, Downey A, Brown B, Chaykosky D, Wolff A, Smith M, Gong MN, Sevransky JE, Lat I, On behalf of the VOLUME-CHASERS Study group and SCCM Discovery Network: Evaluation of vasopressor exposure and mortality in patients with septic shock. Critical Care Medicine 48(10): 1445-1453, Oct 2020.
Miano TA, Lautenbach E, Wilson FP, Guo W, Borovskiy Y, Hennessy S: Incidence and Time Course of Colistin Associated Acute Kidney Injury. Clinical Journal of the American Society of Nephrology 13(4): 542-550, April 2018.
Heavner MS, Gorman EF, Linn DD, Yeung SYA, Miano TA.: Systematic review and meta-analysis of the correlation between bispectral index (BIS) and clinical sedation scales: towards defining the role of BIS in critically ill patients. Pharmacotherapy 42(8): 667-676, August 2022.
Miano TA, Cuker A, Christie JD, Martin N, Smith B, Makley AT, Guo W, Hennessy S: Comparative Effectiveness of Enoxaparin vs. Dalteparin for Thromboprophylaxis after Traumatic Injury. Chest 153(1): 133-142, January 2018.